<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id><journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">4040</journal-id><journal-id journal-id-type="pmc-domain">narcan</journal-id><journal-id journal-id-type="publisher-id">narcancer</journal-id><journal-title-group><journal-title>NAR Cancer</journal-title></journal-title-group><issn pub-type="epub">2632-8674</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12754784</article-id><article-id pub-id-type="pmcid-ver">PMC12754784.1</article-id><article-id pub-id-type="pmcaid">12754784</article-id><article-id pub-id-type="pmcaiid">12754784</article-id><article-id pub-id-type="pmid">41480636</article-id><article-id pub-id-type="doi">10.1093/narcan/zcaf056</article-id><article-id pub-id-type="publisher-id">zcaf056</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Manipulating DNA repair and the DNA damage response to improve cancer therapy</subject><subj-group subj-group-type="category-toc-heading"><subject>Critical Reviews and Perspectives</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/SCI00030</subject><subject>AcademicSubjects/SCI00980</subject><subject>AcademicSubjects/SCI01060</subject><subject>AcademicSubjects/SCI01140</subject><subject>AcademicSubjects/SCI01180</subject></subj-group></article-categories><title-group><article-title>The alternative lengthening of telomeres pathway through a DNA repair lens: mechanism and therapeutic opportunities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Muoio</surname><given-names initials="D">Daniela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="lead">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="supporting">Writing - review &amp; editing</role><aff>
<institution>UPMC Hillman Cancer Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute</institution>, <addr-line>Pittsburgh, PA 15213</addr-line>, <country country="US">United States</country></aff><xref rid="COR2" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2542-2563</contrib-id><name name-style="western"><surname>Fouquerel</surname><given-names initials="E">Elise</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition" degree-contribution="lead">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="lead">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation" degree-contribution="lead">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing" degree-contribution="lead">Writing - review &amp; editing</role><aff>
<institution>UPMC Hillman Cancer Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute</institution>, <addr-line>Pittsburgh, PA 15213</addr-line>, <country country="US">United States</country></aff><xref rid="COR1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="COR1">To whom correspondence should be addressed. Email: <email>elf115@pitt.edu</email></corresp><corresp id="COR2">Correspondence may also be addressed to Daniela Muoio. Email: <email>dam387@pitt.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-12-31"><day>31</day><month>12</month><year>2025</year></pub-date><volume>7</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498459</issue-id><elocation-id>zcaf056</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-02 11:25:13.197"><day>02</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Published by Oxford University Press 2025.</copyright-statement><copyright-year>2025</copyright-year><license><license-p>This work is written by (a) US Government employee(s) and is in the public domain in the US.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zcaf056.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zcaf056.pdf"/><abstract><title>Abstract</title><p>The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent telomere maintenance mechanism leveraged by a subset of human cancers. In these tumors, telomere DNA synthesis is achieved via homologous recombination-based mechanisms. ALT-positive tumors harbor distinctive hallmarks, including heterogeneous telomere lengths, the presence of ALT-associated PML bodies, extrachromosomal telomeric repeats, telomere fragility, and mitotic DNA synthesis. These features reflect underlying replication stress and deregulated DNA repair mechanisms. ALT is associated with various tumor types and can often contribute to worsening the patient&#8217;s prognosis. Strikingly, ALT cancers are particularly enriched in childhood cancers, especially in high-grade gliomas, neuroblastoma, and osteosarcomas, three cancer types that are very common in children. Here, we provide a comprehensive review of the DNA repair factors that drive ALT activation and maintenance and explore emerging therapeutic opportunities associated with the selective dependence of ALT cancer cells on these specific DNA damage response factors. We aim to promote a growing interest in deciphering the DNA-repair-dependent mechanisms of ALT, ultimately helping to build a foundation for the discovery of novel therapeutics against aggressive ALT tumors, for which prognosis is particularly poor and treatments are currently severely lacking.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="zcaf056figgra1.jpg"/></fig>
</p></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R35GM142982</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>UPMC Hillman Cancer Center</institution><institution-id institution-id-type="DOI">10.13039/100030715</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>